Multiple myeloma is the second most common type of blood cancer, with approximately 450 new cases diagnosed annually in Norway
By Danélia Botes
March 29, 2023
A health technology assessment (HTA) of treatment regimens for patients with multiple myeloma in Norway was done. The goals of treatment are to prolong life, achieve a strong response without side effects, and maintain quality of life.
The article discusses the uncertainty surrounding the results of a health economic analysis of treatment regimens for multiple myeloma. The uncertainty is due to reliance on component network meta-analysis and lack of access to patient level data. The methods used to derive underlying survival curves may overestimate treatment costs due to inaccurate accounting for dose reductions during treatment.
The difficulty in drawing clear conclusions about the most effective treatment regimen for patients with refractory or relapsed multiple myeloma is clear. The six triplet combinations mentioned have favourable hazard ratios for overall survival, but there is substantial uncertainty in the evidence. Cost-effectiveness results are also uncertain and need to be viewed in the context of each reference group. Only seven treatments were not dominated by others. Patients with RRMM may lose 12-15 healthy life-years, and there is a high degree of uncertainty in the cost-effectiveness results.
📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill
Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here
📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.